Comparison 4. Induction‐Maintance strategy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Increase in CD4% from baseline at week 36	1	228	Mean Difference (IV, Fixed, 95% CI)	2.90 [0.80, 5.00]
2 Increase in CD4% from baseline at week 72	1	225	Mean Difference (IV, Fixed, 95% CI)	0.60 [‐1.56, 2.76]
3 Increase in CD4% from baseline at week 144	1	228	Mean Difference (IV, Fixed, 95% CI)	0.5 [‐1.70, 2.70]
4 Virologic response (VL<400 copies/ml) at 24 weeks	1	268	Odds Ratio (M‐H, Fixed, 95% CI)	1.99 [1.09, 3.62]
5 Virologic response (VL<400 copies/ml) at 36 weeks	1	312	Odds Ratio (M‐H, Fixed, 95% CI)	1.28 [0.73, 2.23]
6 Virologic response (VL<400 copies/ml) at 48 weeks	1	195	Odds Ratio (M‐H, Fixed, 95% CI)	0.96 [0.50, 1.83]
7 Virologic response (VL<400 copies/ml) at 144 weeks	1	199	Odds Ratio (M‐H, Fixed, 95% CI)	1.03 [0.51, 2.07]
8 Mortality	1		Hazard Ratio (Random, 95% CI)	0.71 [0.16, 3.21]
9 New WHO 4/death event‐free survival	1		Hazard Ratio (Fixed, 95% CI)	0.73 [0.25, 2.12]
10 New WHO 3/4/death event‐free survival	1		Hazard Ratio (Fixed, 95% CI)	0.98 [0.51, 1.90]